MGRM Monogram Technologies Inc

Pfizer reports clinical study results SOUTH SAN FRANCISCO, Calif., July 25 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. (NASDAQ:MGRM) announced today that its collaborator Pfizer Inc (NYSE:PFE) has reported results of a phase III study of its investigational HIV medication, maraviroc, for treatment-naive adult patients infected with CCR5-tropic HIV-1. The data was reported by Pfizer at the International Aids Society conference in Sydney, Australia. "Pfizer's results indicate reduction in viral load and increased CD4 counts," said Christos Petropoulos, Monogram Chief Scientific Officer. "In addition, the trial showed a safety profile that was better than in the control arm. This further supports the safety of maraviroc as a new treatment option for treatment-experienced patients." Monogram's Trofile(TM) Assay has been used to select patients for all of the drug's clinical trials. Pfizer has previously reported 24 week data from its phase III trials of maraviroc in treatment-experienced patients and has recently announced that the 48 week analysis has confirmed these 24 week findings. An NDA is pending with the U.S. Food and Drug Administration and an approvable letter has been received from the F.D.A. in respect of the use of maraviroc in treatment- experienced patients. The data reported today by Pfizer is in respect of a potential new indication in treatment-naive patients that would be subject to a separate FDA submission. About Monogram Biosciences, Inc. Monogram is advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases and cancer. The Company's products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company's technology is also being used by numerous biopharmaceutical companies to develop new and improved antiviral therapeutics and vaccines as well as targeted cancer therapeutics. More information about the Company and its technology can be found on its web site at http://www.monogrambio.com/. Forward-Looking Statements Certain statements in this press release are forward-looking. These forward-looking statements include references to the potential use of our Trofile Assay as a molecular diagnostic for patient selection for Pfizer's CCR5 antagonist maraviroc, if approved by the FDA and European authorities, and the potential approval of maraviroc for use in treatment-na�ve patients. These forward-looking statements are subject to risks and uncertainties and other factors, which may cause actual results to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that regulatory authorities may not require a molecular diagnostic for patient selection for maraviroc; the risk that maraviroc will not be approved by the FDA or European authorities for use in treatment-experienced patients; the risk that Pfizer will not submit marketing applications for use of maraviroc in treatment-na�ve patients and that the FDA will not approve such marketing applications; risks related to the implementation of the collaboration with Pfizer; risks associated with establishing and maintaining logistics arrangements in European and other non-U.S. markets for Trofile; risks and uncertainties relating to the performance of our products; the growth in revenues and actual market acceptance of our products; the impact of competition; whether payors will authorize reimbursement for our Trofile; whether the FDA or any other agency will decide to further regulate Trofile and our other products; the ultimate validity and enforceability of our patent applications and patents; the possible infringement of the intellectual property of others; whether licenses to third party technology will be available; and whether we will be able to raise sufficient capital in the future, if required. For a discussion of other factors that may cause our actual events to differ from those projected, please refer to our most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other subsequent filings with the Securities and Exchange Commission. We do not undertake, and specifically disclaim any obligation, to revise any forward-looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such statements. Trofile is a trademark of Monogram Biosciences, Inc. Contacts: Alfred G. Merriweather Jeremiah Hall Chief Financial Officer Feinstein Kean Healthcare Tel: 650 624-4576 Tel: 415 677-2700 amerriweather@ jeremiah.hall@ monogrambio.com fkhealth.com DATASOURCE: Monogram Biosciences, Inc. CONTACT: Alfred G. Merriweather, Chief Financial Officer of Monogram Biosciences, Inc., +1-650 624-4576, , or Jeremiah Hall of Feinstein Kean Healthcare, +1-415-677-2700, , for Monogram Biosciences, Inc. Web site: http://www.monogrambio.com/

Copyright